跳至主要内容
临床试验/NCT03674372
NCT03674372招募中不适用

Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Severe Right and Left Congenital Diaphragmatic Hernia (CDH)

University of Colorado, Denver2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2018年11月16日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
10
试验地点
2
主要终点
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

研究概览

简要总结

The purpose of this research study is to see if the FETO surgery and FETO release (surgery to remove the device) works and is safe for babies with severe right or left Congenital Diaphragmatic Hernia (CDH). CDH is a condition in which a hole in the baby's diaphragm allows the abdominal organs to move into the chest and limit lung growth. The goal of the FETO device is to block the airway with a balloon-type device, allowing fluid to build up and help the unborn baby's lungs grow. Bigger lungs may improve the baby's quality of life.

详细描述

Despite advances in prenatal diagnosis and postnatal therapies, including extracorporeal membrane oxygenation (ECMO), inhaled nitric oxide therapy, and ventilator strategies that minimize ventilator-induced lung injury, morbidity and mortality rates for babies with severe CDH remain high. Data from Children's Hospital of Philadelphia (CHOP) between January 2006 and December 2010 for prenatal and postnatal care for 64 patients with isolated left CDH showed overall survival was 63%. Survival was 33% in patients requiring the use ECMO. Immediate morbidity/mortality is related to the severity of the pulmonary hypoplasia caused by the mass effect of the herniated abdominal contents on the developing lungs. Quantifying the severity of pulmonary hypoplasia has been performed using the observed/expected lung to head circumference ratio (O/E LHR). It is a tool validated in 354 fetuses with unilateral isolated CDH evaluated between 18 and 38 weeks gestation. For O/E LHR < 25%, survival was dismal at 1/9 or 11% (CHOP experience, not published). Published data from an interdisciplinary follow-up program at CHOP shows striking morbidities in neuromuscular tone and neurodevelopmental status.

The rationale for fetal therapy in severe CDH is to improve fetal lung growth and therefore neonatal survival. Prenatal tracheal occlusion obstructs the normal egress of lung fluid during pulmonary development leading to increased lung tissue stretch, increased cell proliferation, and accelerated lung growth. European colleagues have developed foregut endoscopy and techniques to position and remove endoluminal tracheal balloons in utero. Recently, the Belgium group published summary results of FETO showing an improved survival in 175 patients with isolated left CDH from 24% to 49%.

The investigators goal with this pilot study is to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH (O/E< 25%; O/E < 30%) and right CDH (O/E < 45%).

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Pregnant women age 18 years and older, who are able to consent
  • Singleton pregnancy
  • Normal Karyotype
  • Fetal Diagnosis of Isolated Left or Right CDH with liver up
  • Gestation at enrollment prior to 29 wks plus 6 days
  • SEVERE pulmonary hypoplasia with Ultra Sound L-sided O/E LHR < 25% or R-sided O/E LHR <45%

排除标准

  • Pregnant women <18 years of age.
  • Maternal contraindication to fetoscopic surgery or severe maternal medical condition in pregnancy
  • Technical limitations precluding fetoscopic surgery
  • Rubber latex allergy
  • Preterm labor, cervix shortened (<15 mm at enrollment or within 24 hours of FETO balloon insertion procedure) or uterine anomaly strongly predisposing to preterm labor, placenta previa
  • Psychosocial ineligibility, precluding consent
  • Inability to remain at FETO site during time period of tracheal occlusion, delivery and postnatal care

研究组 & 干预措施

Fetuses with L- sided CDH with O/E LHR <30%.

Experimental

Fetuses with Left CDH (O/E LHR < 30%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)

干预措施: Fetoscopic Endoluminal Tracheal Occlusion (FETO) (Device)

Fetuses with Left CDH (O/E LHR < 25%)

Experimental

Fetuses with Left CDH (O/E LHR < 25%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)

干预措施: Fetoscopic Endoluminal Tracheal Occlusion (FETO) (Device)

Fetuses with R- sided CDH with O/E LHR < 45%

Experimental

Fetuses with Right CDH (O/E LHR < 45%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)

干预措施: Fetoscopic Endoluminal Tracheal Occlusion (FETO) (Device)

结局指标

主要结局

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

时间窗: After Insertion of Balloon to delivery- (from 27 weeks gestational age up to 39 weeks gestational age)

Incidence of Maternal complications: preterm labor, premature rupture of membranes, oligohydramnios, polyhydramnios, chorioamnionitis)

Successful placement of Balt Goldbal2 balloon

时间窗: 7 weeks after placement

The feasibility of performing the procedure and managing the pregnancy during the period of tracheal occlusion

Successful removal of Balt Goldbal2 balloon

时间窗: Within 5 weeks prior to delivery

The feasibility of the removal of the device prior to delivery

Gestational age at delivery

时间窗: At delivery

次要结局

  • Survival at Discharge or at 6 months if still hospitalized(Discharge up to 180 days post delivery)
  • Lung Volume Measurement(7 weeks after placement of balloon)
  • Lung Head Ratio Measurement(7 weeks after placement of balloon)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验